November 8, 2024
Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth
Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues
Daiichi Sankyo and Alteogen Collaborate on Subcutaneous Enhertu Development in $300M Licensing Agreement
Daiichi Sankyo, Alteogen, subcutaneous Enhertu, $300M licensing deal, human hyaluronidase, cancer treatment
Charles River Laboratories Embarks on Restructuring, Closing 15 Smaller Sites Amid Declining Demand for Early Research Services
Charles River Laboratories, restructuring, site closures, declining demand, early research services, cost-cutting measures, biotech industry challenges.
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Private Equity Deal
Avid Bioservices, GHO Capital Partners, Ampersand Capital Partners, biologics CDMO, private equity acquisition, $1.1 billion deal
Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs
Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization
UK Health Secretary Warns Against Misuse of GLP-1 Weight Loss Drugs for Aesthetic Purposes
GLP-1 agonists, weight loss drugs, misuse, aesthetic weight loss, UK health secretary, MHRA warnings
Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A
Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.
Rapport Therapeutics Faces Regulatory Hurdles in Pain Treatment Trials
Rapport Therapeutics, pain treatment trials, regulatory challenges, RAP-219, clinical development
Moderna’s COVID-19 Vaccine Sales Exceed Expectations, but RSV Vaccine Falls Short
Moderna, COVID-19 vaccine, RSV vaccine, vaccine sales, pharmaceutical industry
Sarepta Discontinues Development of SRP-5051 for Duchenne Muscular Dystrophy Due to Safety Concerns
Sarepta Therapeutics, SRP-5051, Duchenne muscular dystrophy, DMD, safety concerns, hypomagnesemia, FDA, clinical trials